The Department of Dermatovenereology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Immun Inflamm Dis. 2021 Sep;9(3):667-680. doi: 10.1002/iid3.415. Epub 2021 May 5.
Candida albicans, the main human fungal pathogen, can cause fungal infection and seriously affect people's health and life. This study aimed to investigate the effects of ritonavir (RIT) on C. albicans and the correlation between SAP2 as well as ERG11 and drug resistance.
Secreted aspartyl proteinases (Saps) activities and pathogenicity of C. albicans with different drug resistance were measured. M27-A4 broth microdilution method was used to analyze the drug sensitivity of RIT combined with fluconazole (FCA) on C. albicans. After that, SAP2 and ERG11 mutations were examined by polymerase chain reaction (PCR) and sequencing, and quantitative real-time PCR was utilized to determine the expression of the two genes. By analyzing pz values, the Saps activity of cross-resistant strains was the highest, followed by voriconazole (VRC)-resistant strains, FCA-resistant strains, itraconazole (ITR)-resistant strains, and sensitive strains. The pathogenicity of C. albicans in descending order was as follows: cross-resistant strains, VRC-resistant strains, ITR-resistant strains, FCA-resistant strains, and sensitive strains. With the increase of RIT concentrations, the Saps activity was gradually inhibited. Drug sensitivity results showed that there was no synergistic effect between RIT and FCA. Additionally, no gene mutation sites were found in SAP2 sequencing, and 17 synonymous mutations and 6 missense mutations occurred in ERG11 sequencing. Finally, the expression of SAP2 and ERG11 was significantly higher in the resistant strains compared with the sensitive strains, and there was a positive liner correlation between SAP2 and ERG11 messenger RNA expression (r = .6655, p < .001).
These findings may help to improve our understanding of azole-resistant mechanisms of C. albicans and provide a novel direction for clinical therapeutics of C. albicans infection.
白色念珠菌是主要的人类真菌病原体,可引起真菌感染,严重影响人们的健康和生活。本研究旨在探讨利托那韦(RIT)对白色念珠菌的影响,以及 SAP2 和 ERG11 与耐药性的相关性。
测定了不同耐药性白色念珠菌的分泌天冬氨酸蛋白酶(Saps)活性和致病性。采用 M27-A4 肉汤微量稀释法分析 RIT 联合氟康唑(FCA)对白色念珠菌的药敏性。然后,通过聚合酶链反应(PCR)和测序检测 SAP2 和 ERG11 突变,并采用定量实时 PCR 测定两个基因的表达。通过分析 pz 值,发现交叉耐药株的 Saps 活性最高,其次是伏立康唑(VRC)耐药株、FCA 耐药株、伊曲康唑(ITR)耐药株和敏感株。白色念珠菌的致病性依次为:交叉耐药株、VRC 耐药株、ITR 耐药株、FCA 耐药株和敏感株。随着 RIT 浓度的增加,Saps 活性逐渐受到抑制。药敏结果显示,RIT 与 FCA 之间无协同作用。此外,SAP2 测序未发现基因突变位点,ERG11 测序发现 17 个同义突变和 6 个错义突变。最后,耐药株 SAP2 和 ERG11 的表达明显高于敏感株,SAP2 和 ERG11 信使 RNA 表达之间呈正线性相关(r =.6655,p <.001)。
这些发现可能有助于提高我们对白色念珠菌唑类耐药机制的认识,并为白色念珠菌感染的临床治疗提供新的方向。